Recce Pharmaceuticals (ASX:RCE)
ASX announcement history & article coverage
Transparent by design.
Announcments by Recce Pharmaceuticals (ASX:RCE) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notice of Annual General Meeting/Proxy Form
Notification of cessation of securities - RCE
Resolutions under section 249N of the Corporations Act
2026 Annual General Meeting
Results of General Meeting
General Meeting Presentation
Appendix 4G
Appendix 4E and FY26 Annual Report
Recce Pharmaceuticals reports reduced loss and advances Phase 3 trials for RECCE® 327 with key regulatory and commercial milestones
HREC Approves Comparator Study for Pivotal Phase 3 DFI
Recce Pharmaceuticals expands Phase 3 DFI trial with active-controlled comparator arm in Australia
Change of Director's Interest Notices (x4)
Cleansing Notice
Application for quotation of securities - RCE
Completion of Share Purchase Plan and Shortfall Notice
Application for quotation of securities - RCE
Notice of General Meeting/Proxy Form
U.S. Government Releases US$66.9B AMR Biodefense Strategy
Investor Webinar - Q4 FY26 Investor Presentation Deck
Investor Webinar - 2.30PM (AEST) 21 July 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Recce Pharmaceuticals advances Phase 3 trials and signs licensing term sheet with Middle Eastern pharma
Update - Proposed issue of securities - RCE
Extension to Share Purchase Plan Closing Date